Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
KRYS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$141.72 - $219.34
Previous CloseN/A
Volume44.50K
Average Volume (3M)286.79K
Market Cap
$5.30B
Enterprise Value$4.09B
Total Cash (Recent Filing)$1.96M
Total Debt (Recent Filing)$2.14M
Price to Earnings (P/E)61.6
Beta1.07
Next Earnings
May 12, 2025EPS Estimate
1.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.99
Shares Outstanding28,806,078
10 Day Avg. Volume251,294
30 Day Avg. Volume286,792
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)N/A
Price to Sales (P/S)18.56
Price to Cash Flow (P/CF)25.50
P/FCF Ratio25.90
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.13
Enterprise Value/Ebitda43.17
Forecast
1Y Price Target
$218.14Price Target Upside20.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Krystal Biotech News
PremiumCompany Announcements
Krystal Biotech Earnings Call: Optimism Amid Challenges---
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageThe company's proprietary technology and lack of viable competitors strengthen its market position, reducing the likelihood of biosimilar threats.
Market ExpansionKrystal Biotech is poised for significant revenue growth through global market penetration, including major countries in the EU and Japan, potentially doubling the US market size.
Regulatory ApprovalKRYS received a positive CHMP opinion for Vyjuvek for the treatment of wounds in DEB patients from birth.
Bears Say
Compliance ChallengesVyjuvek sales of $91.1M were in-line with consensus of $92.5M as management continues to guide to a gradual decrease in compliance.
Patient EngagementThe fraction of new writers has decreased as patients settle into a routine maintenance regimen.
---
Ownership Overview
22.63% Insiders
34.60% Mutual Funds
0.05% Other Institutional Investors
18.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $141.72 and its highest was $219.34 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $5.30B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is May 12, 2025 which is in 41 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on Feb 19, 2025. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.184 by $0.336.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 1.48.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 28,806,078 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $1.52 in its last earnings report, beating expectations of $1.184. Following the earnings report the stock price went up 12.432%.
Which hedge fund is a major shareholder of Krystal Biotech?
Currently, no hedge funds are holding shares in KRYS
---
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$218.14 (20.99% Upside)
$218.14 (20.99% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 19.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $106.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 37.9%
Last 30 Days ▲ 37.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.36%
12-Months-Change
Fundamentals
Return on Equity
10.34%
Trailing 12-Months
Asset Growth
29.02%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
---
KRYS Company Deck
---
KRYS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, successful VYJUVEK launch, and robust pipeline developments. However, challenges in patient compliance, operational delays, and increased expenses were noted. The company's strategic plans for global expansion and future growth provide a positive outlook.Read More>---
KRYS Stock 12 Month Forecast
Average Price Target
$218.14
▲(20.99% Upside)
Technical Analysis
Sarepta Therapeutics
―
Bluebird Bio
―
uniQure
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering KRYS
1 Year
1 Year Success Rate
16/16 ratings generated profit
1 Year Average Return
+45.26%
reiterated a buy rating last month
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +45.26% per trade.
---